Shrinks In Sneakers

Tag: mental health law

  • Psychiatry Is on Trial. We Should Not Plead Guilty to the Wrong Charges

    Psychiatry Is on Trial. We Should Not Plead Guilty to the Wrong Charges

    Psychiatry is on trial. It was probably inevitable. A field that treats suffering, suicide, psychosis, trauma, addiction, violence risk, loneliness, despair, and meaninglessness was always going to be dragged into the political arena. Psychiatry sits at the intersection of medicine, culture, family trauma, public fear, pharmaceutical influence, personal liberty, and moral injury. That makes it uniquely vulnerable to distortion.

    But the current moment feels different.

    With Health and Human Services Secretary Robert F. Kennedy Jr. placing psychiatric medications and “overmedicalization” at the center of federal attention, psychiatry is no longer only being debated in journals, clinics, and academic conferences. It is being litigated in public. Increasingly, it is also being litigated in court. On May 4, 2026, HHS announced a MAHA action plan aimed at curbing psychiatric overprescribing, promoting informed consent, shared decision-making, nonmedication interventions, and deprescribing when clinically indicated.1

    Some of that language is reasonable. In fact, many psychiatrists already agree with it.

    Psychiatric medications should not be the default response to every form of human distress. Patients deserve informed consent. Deprescribing should be part of competent care. Psychotherapy, exercise, sleep, nutrition, family support, social connection, and meaning making should not be treated as decorative add-ons. They are often central to recovery.

    But that is not the same as saying psychiatric illness is not real. It is not the same as implying psychiatric medications are broadly dangerous, unnecessary, or responsible for America’s mental health crisis. And it is certainly not the same as turning painful anecdotes into national policy.

    That is where psychiatry must draw the line.

    The American Psychiatric Association has appropriately pushed back on the idea that the mental health crisis can be reduced to overprescribing, noting that this framing ignores workforce shortages, limited access to care, lack of psychiatric beds, and uneven distribution of evidence-based treatment.2 That is exactly right. Deprescribing may be good medicine in selected cases. But deprescribing is not a national mental health strategy.

    It is a clinical tool.

    There is a dangerous pattern in the current conversation. A public figure describes a deeply personal experience: a family member struggles to discontinue an antidepressant, someone feels emotionally blunted on medication, a young adult regrets being started on an SSRI as a teenager, or a patient develops withdrawal symptoms after stopping too quickly. The story is real. The suffering is real. The problem deserves attention.

    But then the anecdote becomes a theory of psychiatry.

    The assumption becomes: because this happened to someone I love, this must be what psychiatry is doing to the country.

    That is not science. That is narrative capture.

    Psychiatry should not dismiss these stories. We should listen to them. We should admit that antidepressant discontinuation can be difficult for some patients. We should acknowledge that medications are sometimes started without a clear enough plan, continued without adequate review, and stopped too abruptly. We should be honest that some patients are placed on medication when what they needed first was psychotherapy, time, structure, sleep, exercise, substance use treatment, grief work, family intervention, or a change in environment.

    But honesty cuts both ways.

    Some patients are not “overmedicalized.” They are undertreated. Some are not being harmed by psychiatry. They are being harmed by the absence of psychiatry. Some patients do not need fewer medications. They need the right diagnosis, the right medication, the right dose, the right monitoring, the right therapy, and a system that does not abandon them after discharge.

    I work in real-world psychiatry. I have seen patients whose lives were devastated by undertreated depression, bipolar disorder, psychosis, catatonia, OCD, addiction, and trauma. I have also seen patients placed on medications they did not need, for longer than necessary, without enough discussion about risks, benefits, alternatives, or exit strategies. Both realities are true.

    That is the entire point.

    Psychiatry’s critics often want one story. The real world gives us several.

    Psychiatric medications can be overused. They can also be lifesaving.

    Antidepressants can cause side effects. They can also help patients return to work, reconnect with family, survive suicidal depression, and function again.

    Stopping medication can produce withdrawal symptoms. Stopping medication can also reveal relapse of the underlying illness. Clinically, those are not always easy to separate, and the distinction matters.

    Psychiatry has a difficult history. It also remains one of the few medical specialties willing to sit with the most frightening, stigmatized, and disabling forms of human suffering.

    The field does not need denial. It needs precision.

    One of the most important reforms psychiatry should embrace is building the off-ramp into treatment from the beginning. When starting an antidepressant, clinicians should discuss expected duration, criteria for continuation, warning signs of relapse, tapering principles, and what remission means. Patients should know that medication is not a moral failure, not a life sentence, and not something to stop abruptly to prove toughness.

    Abrupt discontinuation is not courage. It is usually bad medicine.

    And it is not only psychiatrists saying so. The American Foundation for Suicide Prevention, responding directly to the HHS action plan, warned that “abrupt discontinuation or inappropriate ‘deprescribing,’ particularly outside a collaborative patient-provider process, can increase risk, including the potential for symptom relapse and elevated suicide risk for some individuals.”3 AFSP also reaffirmed what decades of clinical trials, population-level studies, and health system data have shown: judicious use of antidepressants reduces suicide risk overall.3

    That is the suicide prevention community speaking. Not the pharmaceutical industry. Not organized psychiatry. The organization whose entire mission is keeping people alive.

    If HHS wants to support better tapering education, better informed consent, better access to psychotherapy, and better reimbursement for clinicians who take the time to deprescribe carefully, psychiatry should welcome that. In fact, we should lead it. The HHS action plan specifically emphasizes informed consent, shared decision-making, review of risks and benefits, nonmedication approaches, and tapering when patients are not experiencing clinical benefit.1 Those are not anti-psychiatry principles. Done correctly, they are good psychiatry.

    But the same public conversation has also entertained the claim that psychiatric medications cause mass shootings, a claim that has been repeatedly examined and found to lack credible scientific support. When prominent voices repeat it anyway, the harm is not abstract. Patients hear it. Families hear it. Lawmakers hear it. People already afraid of treatment become more afraid. Stigma grows. Care is delayed.

    And delayed care kills. AFSP said as much in its response to this action plan.3

    Psychiatry should not respond to this moment by becoming reflexively defensive. We should not pretend the field has always gotten it right. We have not. We should not deny withdrawal, side effects, diagnostic uncertainty, pharmaceutical influence, rushed prescribing, or the medicalization of ordinary distress. Those criticisms contain enough truth that ignoring them would be a mistake.

    But we should also refuse to accept a false indictment.

    The problem is not that psychiatry exists. The problem is that too many Americans receive fragmented, rushed, algorithmic, poorly monitored, under-resourced mental health care and then call that psychiatry.

    The problem is not that antidepressants are prescribed. The problem is that they are sometimes prescribed without enough diagnostic clarity, psychotherapy access, follow-up, deprescribing planning, or attention to the difference between illness and distress.

    The problem is not that psychiatrists believe in medication. The problem is that our health care system often reimburses medication management more reliably than psychotherapy, family work, lifestyle intervention, prevention, community support, and time.

    That is not an argument against psychiatry. It is an argument for better psychiatry.

    Psychiatry must be willing to say something politically inconvenient: not all suffering is mental illness, but mental illness is real. Not everyone who is sad needs a diagnosis, but some people with depression will die without treatment. Not every anxious child needs medication, but some children are severely impaired and deserve evidence-based care. Not every patient should remain on an antidepressant indefinitely, but some patients relapse repeatedly when treatment is stopped. Not every psychiatric outcome is preventable, but some bad outcomes occur because systems fail.

    It is possible to do everything right in psychiatry and still have a tragic outcome.

    It is also possible to have a tragic outcome because we did not do enough.

    That distinction is where serious medicine lives.

    This is why psychiatry must reclaim the public narrative. We cannot allow the field to be defined only by its critics, by pharmaceutical marketing, by political theater, or by the most extreme anecdotes on social media. We need to speak plainly to the public.

    Yes, antidepressant withdrawal can happen.

    Yes, some patients are overmedicated.

    Yes, informed consent needs to improve.

    Yes, therapy and lifestyle interventions matter.

    Yes, deprescribing should be part of psychiatric competence.

    And yes, psychiatric medications remain essential treatments for many people with serious and disabling illness.

    The future of psychiatry should not be pill-first. It should not be pill-never. It should be patient-first, diagnosis-first, evidence-first, and humility-first.

    Psychiatry will not survive this moment by going quiet, and it will not survive it by going defensive. It will survive by becoming better, and by saying so out loud.

    We are not the cause of America’s mental health crisis. We are also not its cure. We are physicians treating the most disabling illnesses medicine has ever named, in a system that has never funded us to do it well, in a country that wants the suffering to stop but does not want to pay for the treatment that stops it.

    If HHS wants better psychiatry, psychiatry should be the first to demand it. If patients want safer prescribing, we should be the ones leading it. If the public wants honesty, we should give them more of it than they expected.

    Psychiatry does not need to plead guilty to the wrong charges. But we do need to stop letting other people write the indictment.

    The defense rests when the work begins.

    References

    1. HHS launches MAHA action plan to curb psychiatric overprescribing. US Department of Health and Human Services. News release. May 4, 2026. Accessed May 13, 2026. https://www.hhs.gov/press-room/hhs-launches-maha-action-plan-curb-psychiatric-overprescribing.html

    2. APA welcomes national focus on mental health, urges evidence-based approach and continued focus on access to care. American Psychiatric Association. News release. May 4, 2026. Accessed May 13, 2026.

    3. Moutier CY. AFSP statement on the importance of antidepressants and evidence-based treatment for suicide prevention. American Foundation for Suicide Prevention. News release. May 5, 2026. Accessed May 13, 2026. https://www.prnewswire.com/news-releases/afsp-statement-on-the-importance-of-antidepressants-and-evidence-based-treatment-for-suicide-prevention-302762738.html

    4. Espí Forcén F, Hatters Friedman S. Psychiatry on trial: are psychiatrists responsible for their patients’ criminal behavior? Psychiatric Times. August 27, 2026. Accessed August 29, 2026. https://www.psychiatrictimes.com/view/psychiatry-on-trial-are-psychiatrists-responsible-for-their-patients-criminal-behavior

    Disclaimer: Views are my own not associated with any employer. This is not medical advice, and the information is provided for educational purposes only. Please consult your doctor for any specific medical questions. All content is created for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider. If you think you have a medical emergency, call your doctor, go to the emergency department, or call 911. We do not endorse any specific treatment, tests, or procedures. Reliance on this information is solely at your own risk.

  • Psych Meds Are Not the Enemy. Bad Medicine Is

    Psych Meds Are Not the Enemy. Bad Medicine Is

    There is a dangerous difference between criticizing bad psychiatric practice and stigmatizing psychiatric illness.

    I have criticized aspects of psychiatry many times. I believe our field should be open to critique. We should question our prescribing habits. We should challenge lazy diagnosis. We should acknowledge when medications are used too quickly, continued too long, or substituted for the deeper work of psychotherapy, lifestyle change, social support, and careful clinical formulation.

    Psychiatry should never be above criticism.

    But criticism of psychiatric practice is not the same thing as denying the legitimacy of psychiatric illness.

    And right now, that line is being blurred.

    Serious Mental Illness Is Real

    One thing you will never hear me say is that psychiatric disease is not real.

    Schizophrenia is real.
    Bipolar disorder is real.
    Severe major depression is real.
    Catatonia is real.
    Psychotic depression is real.
    Obsessive-compulsive disorder can be profoundly disabling.
    Posttraumatic stress disorder can devastate a person’s life.

    These are not character flaws. They are not weakness. They are not simply failures of lifestyle, discipline, resilience, spirituality, or mindset.

    They are legitimate medical illnesses.

    That does not mean every painful experience is a disease. It does not mean every person who is grieving, anxious, overwhelmed, lonely, or struggling needs a diagnosis or a medication. In fact, one of the most important tasks in psychiatry is knowing the difference.

    Some people need medication.

    Some people need psychotherapy.

    Some people need sleep, exercise, nutrition, structure, social connection, housing, safety, meaning, accountability, or community.

    Many people need several of these at the same time.

    The goal is not to medicalize all suffering. The goal is to recognize real illness when it is present and treat it with the seriousness it deserves.

    The Problem Is Not “Medication”

    Psychiatric medications are often discussed as if they are inherently suspicious.

    But medication is not the enemy.

    Bad medicine is.

    A medication can be life-changing when used for the right condition, in the right person, at the right time, for the right reason.

    The same medication can be harmful when used carelessly, without a clear diagnosis, without follow-up, without discussion of risks and benefits, or without a plan for reassessment.

    That is not unique to psychiatry.

    Antibiotics can be lifesaving, but inappropriate antibiotic use causes harm. Opioids can be appropriate in some clinical contexts, but reckless prescribing devastated communities. Steroids can be powerful tools, but long-term unnecessary use can create major problems.

    The issue is not whether medications are “good” or “bad.”

    The issue is whether we are practicing medicine well.

    Deprescribing Matters, But It Is Not a Mental Health Policy

    Deprescribing is important.

    Every psychiatrist I know has experience reducing, simplifying, or stopping medications when the risks outweigh the benefits or when the original indication no longer makes sense.

    This is not a fringe idea. It is part of daily psychiatric practice.

    We stop medications that are not helping.
    We reduce unnecessary polypharmacy.
    We simplify regimens when possible.
    We monitor side effects.
    We reassess diagnoses.
    We talk with patients about what still makes sense.

    Good psychiatry includes deprescribing.

    But deprescribing alone will not solve the mental health crisis.

    People cannot deprescribe their way out of a lack of psychiatric beds. They cannot deprescribe their way out of months-long waitlists. They cannot deprescribe their way out of poverty, homelessness, trauma, addiction, loneliness, or a collapsing continuum of care.

    And they cannot deprescribe their way out of schizophrenia, mania, catatonia, psychotic depression, or severe melancholic depression.

    When we frame the mental health crisis primarily as a problem of overprescribing, we oversimplify a system failure.

    We ignore the shortage of psychiatrists. We ignore the lack of access to psychotherapy. We ignore inadequate visit times, fragmented care, insurance barriers, emergency departments boarding psychiatric patients for days, and the near disappearance of a true continuum of care.

    Those are not solved by telling people to take fewer medications.

    The Risk of Stigma Dressed Up as Reform

    My concern is not that we are talking about prescribing quality. We should be talking about that.

    My concern is that the rhetoric around psychiatric medications often sends a dangerous message to people who already feel ashamed.

    Many patients with serious mental illness already struggle with the idea of needing medication.

    They worry it means they are weak.
    They worry it means they are broken.
    They worry it means they are dependent.
    They worry it means they are not trying hard enough.
    They worry others will see them differently.

    When public conversations frame psychiatric medications as the central villain, those patients hear something very different from “we need better prescribing.”

    They hear:

    You are dependent.
    You are addicted.
    You are taking the easy way out.
    You should be able to fix this naturally.
    You are the problem.

    That is not empowerment.

    That is stigma.

    And for some patients, that stigma can be dangerous. It can lead people to stop medications abruptly, avoid treatment, disengage from care, relapse, or delay help until a crisis occurs.

    Of course patients should be informed. Of course they should understand risks and benefits. Of course they should have a voice in treatment decisions.

    But informed consent should not become fear-based messaging. And reform should not become another way of shaming people with serious psychiatric illness.

    Better Medicine Means Holding Two Truths

    The future of psychiatry depends on our ability to hold two truths at the same time.

    First, psychiatric illness is real and can be devastating.

    Second, psychiatry must be careful not to overdiagnose, overprescribe, or turn normal human suffering into lifelong pathology.

    Both truths matter.

    If we only emphasize the first, we risk medicalizing everything.

    If we only emphasize the second, we risk abandoning people with serious illness.

    Real psychiatric care lives in the tension between those truths.

    It requires humility. It requires careful diagnosis. It requires honest conversations about uncertainty. It requires medication when appropriate, psychotherapy when appropriate, lifestyle intervention when appropriate, social support when appropriate, neuromodulation when appropriate, and deprescribing when appropriate.

    It also requires us to say clearly that some people need medication, and that needing medication is not a moral failure.

    The Goal Is Better Medicine

    The goal is not to prescribe more.

    The goal is not to prescribe less.

    The goal is to prescribe better.

    Better diagnosis.
    Better informed consent.
    Better follow-up.
    Better access to psychotherapy.
    Better use of lifestyle interventions.
    Better systems of care.
    Better deprescribing when medications are no longer needed.
    Better protection for people whose medications are the reason they are alive, stable, working, parenting, studying, and functioning.

    We do not fix psychiatry by pretending psychiatric medications are always the answer.

    But we also do not fix psychiatry by pretending they are the enemy.

    Psych meds are not the enemy.

    Bad medicine is.

  • Reject dogma—embrace nuance in Psychiatry

    🔹 Psychoanalysis should not be treated as sacred doctrine. Freud was a clever and influential thinker, but not a prophet.


    🔹 Biological psychiatry is equally vulnerable to dogma. Not every symptom signals a disease, and not every distress warrants medication.


    🔹 That said, evidence-based pharmacology has its place—especially when medications show clear, replicable benefits in defined clinical conditions.

    The future of psychiatry lies in balanced thinking, not blind allegiance—to Freud, to biology, or to any single model of mind.

  • Major Federal Healthcare Cuts: What Physicians Need to Know and How We Can Respond

    Major Federal Healthcare Cuts: What Physicians Need to Know and How We Can Respond

    A devastating blow to public health: More than $12 billion in federal grants—funding that supported infectious disease tracking, mental health services, addiction treatment, and other critical programs—has been canceled as part of recent federal budget cuts.

    These cuts threaten early detection of outbreaks, access to psychiatric care, and lifesaving addiction treatment programs—all areas where we, as physicians, see the impact daily.

    Key Areas Affected:

    🚨 Infectious Disease Surveillance – Reduced ability to track emerging threats like COVID-19, flu, and antibiotic-resistant infections.
    🧠 Mental Health Services – Fewer resources for crisis response teams, community mental health centers, and psychiatric services.
    💉 Addiction Treatment – Less funding for MAT (medication-assisted treatment) and harm reduction programs at a time when overdose rates remain high.
    🏥 Public Health Preparedness – Cuts to pandemic readiness and emergency response training for healthcare workers.

    What Can We Do?

    🔹 Advocate – Contact legislators, professional organizations (APA, AMA, ACP), and demand restoration of funding.
    🔹 Educate – Inform patients and communities about how these cuts impact their care.
    🔹 Mobilize – Work with hospital leadership and local organizations to find alternative funding sources.
    🔹 Collaborate – Strengthen interprofessional partnerships to sustain services despite budget constraints.

    We’ve seen what happens when public health is underfunded—it costs more lives and more money in the long run. We can’t afford to be silent.

  • 🚨 Health Care is Under Attack

    🚨 Health Care is Under Attack

    Our patients are under attack. Our oath to do no harm is under attack. Health care is under attack.

    Last week, the U.S. House of Representatives passed a budget resolution that could slash $880 billion from Medicaid—a devastating blow that would strip 15.9 million people of health coverage. That’s 1 in 5 of your friends, neighbors, and patients.

    📉 Who will suffer most?
    🔹 Children
    🔹 The elderly
    🔹 People with disabilities
    🔹 Those living in poverty

    These are the people we serve every day

    We cannot stand by as essential care is ripped away from the most vulnerable. This is not a red or blue issue —this is a people issue.

    🩺 If you’re a healthcare professional, patient, or advocate, now is the time to speak up. Join us in the fight to protect Medicaid and ensure no one is left behind.

  • The parallels between the psychiatric asylums and modern inpatient psychiatric treatment 

    The parallels between the psychiatric asylums and modern inpatient psychiatric treatment 

    The history of psychiatric asylums is a dark chapter in mental health care, yet the more I reflect on it, the more I see troubling parallels between the asylum era and our modern system of inpatient psychiatric treatment.

    Asylums, in their earliest forms, were created with good intentions: to provide care for those with severe mental illnesses and intellectual disabilities who could not be safely or adequately treated in their communities. However, as these institutions became overcrowded, underfunded, and poorly staffed, they devolved into places of neglect, abuse, and suffering. The eventual closures of these institutions were a necessary response to the horrific conditions exposed, but the underlying issues didn’t disappear. They merely shifted.

    Today, many of the same challenges persist in our modern inpatient psychiatric system. Patients with severe mental illnesses or disabilities still require long-term care, but instead of asylums, they are placed in short-term facilities. These hospitals are often understaffed and overburdened, operating under financial pressures to prioritize quick turnover rather than long-term recovery. It’s not uncommon for patients to be admitted, stabilized just enough for discharge, and then readmitted within weeks—sometimes even days—because the core issues remain unaddressed.

    In both the asylums of the past and the short-term psychiatric hospitals of today, patients often receive the same types of medications and therapies. The difference is that today’s treatment settings operate under stricter legal frameworks aimed at preserving patient rights, but the lack of continuity and depth in treatment results in a revolving door of care. Rather than focusing on sustained recovery, the focus is often on crisis management and meeting insurance-imposed timelines.

    This cycle is problematic for patients and clinicians alike. For patients, it results in frustration, instability, and a lack of meaningful progress. For healthcare workers, it leads to burnout, similar to what was seen in the asylum era. The system, despite its modern façade, hasn’t evolved enough to address the long-term needs of individuals with severe mental illnesses. Until we invest in creating a system that prioritizes long-term, comprehensive care, we risk repeating the mistakes of the past—only this time without the walls of the asylum to contain the issue.

  • Have We Truly Moved Beyond the Asylum? Rethinking Modern Mental Health Care

    Have We Truly Moved Beyond the Asylum? Rethinking Modern Mental Health Care

    It’s that time of year when fall festivities begin, bringing with them the comforting embrace of pumpkin spice and the thrill of Halloween fun. Over the weekend, I visited Pennhurst Asylum to experience its haunted attractions. While it’s all good fun and purely fictional, it stands in stark contrast to the true horrors that once existed within asylums. I learned a great deal about Pennhurst’s tragic history—how it was eventually shut down due to horrendous living conditions, rampant abuse, lack of proper care, and the heartbreaking deaths of many patients.

    The concept of an asylum was originally born from good intentions. There was a need for a controlled, carefully monitored environment where individuals with severe mental illnesses and intellectual disabilities could receive care when it couldn’t be provided at home. However, these institutions quickly became overcrowded and severely underfunded, leading to dangerous conditions and substandard care. When you listen to interviews with former staff, it becomes painfully clear that most of them genuinely wanted to help, but they were overwhelmed by the lack of resources and growing patient populations, which ultimately led to burnout and a breakdown in the system.

    What struck me the most during my visit is how little our modern mental health system has progressed beyond the asylum model. While the walls of these institutions may have crumbled, the systemic issues remain. We still face a severe shortage of resources, and we still have large populations of patients with serious mental illnesses or intellectual disabilities, conditions that we have yet to find effective cures for. The difference now is that the burden has shifted to short-term inpatient facilities, where it’s not uncommon to treat and discharge the same patient multiple times within a single month. These patients deserve a place where they can receive long-term, consistent treatment and careful observation—certainly more than just five to seven days.

    The problem is multifaceted. It involves the tension between patients’ rights, insurance companies, and the pressure to generate profit from the care delivered. We find ourselves in a vicious cycle where patients make minimal progress with short-term interventions, are discharged, and quickly decompensate upon returning to the community. In many ways, the same forms of therapy and the same medications that were used in asylums are being employed today in these short-term facilities.

    While I’d like to be hopeful, I can’t help but see the striking parallels between our current system and the asylums of the past. Unfortunately, the evolution of mental health care feels more like a lateral move than a leap forward. Until we address the root issues—underfunding, understaffing, and the over-reliance on short-term fixes—it’s difficult to imagine real progress.

  • Locked Out: Why Most Inmates Are Denied Life-Saving Opioid Treatment

    Locked Out: Why Most Inmates Are Denied Life-Saving Opioid Treatment

    The JAMA Network Open article titled “Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails” investigates the availability of medications for opioid use disorder (MOUD) in U.S. jails, such as methadone, buprenorphine, and naltrexone. It highlights that MOUD, which is a critical component in treating opioid use disorder (OUD), is underutilized in correctional facilities, despite its effectiveness in reducing overdose rates, withdrawal symptoms, and recidivism.

    Key factors influencing MOUD availability in jails include jail size, regional location, the political landscape, and resources available in the facility. Jails in larger urban areas or those in states with Medicaid expansion are more likely to provide MOUD. Barriers such as stigma, lack of funding, and inadequate healthcare infrastructure also limit access to these medications.

    The study emphasizes the importance of expanding access to MOUD in jails to address the opioid epidemic and improve public health outcomes for incarcerated populations as only 44% of jails offer MOUD in the current system. 

  • Strengthening Mental Health Parity: Ensuring Equal Access to Affordable Care

    Strengthening Mental Health Parity: Ensuring Equal Access to Affordable Care

    Here are the key points from the Biden Administration’s finalized regulation:

    1. Objective: To ensure 175 million Americans with private health insurance have access to affordable mental health services.
    2. Focus: The regulation emphasizes mental health care parity, aiming for equal access and affordability between mental and physical health services.
    3. Requirements for Insurers: Health insurance providers must cover mental health services comparably to physical health services, without added hurdles.
    4. Implementation: Insurers are required to assess the adequacy of their mental health networks and take corrective action if they fall short.
    5. Broader Impact: The rule seeks to reduce out-of-pocket costs and improve access to essential mental health treatments, addressing the growing mental health crisis.